Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
about
Medication-related osteonecrosis of the jaw: Clinical and practical guidelinesHypercalcemia of malignancy and new treatment optionsPlatelet-Rich Plasma in Treatment of Zoledronic Acid-Induced Bisphosphonate-related Osteonecrosis of the Jaws.Current and future directions in medical therapy: hypercalcemia.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network.Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesSystematic review of bisphosphonates for hypercalcaemia of malignancy.Development of animal model for Bisphosphonates-related osteonecrosis of the jaw (BRONJ)Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.[Hypercalcemia in cancer patients. Who, when and how to treat?]De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.The evidence base of palliative medicine: is inpatient palliative medicine evidence-based?Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients.Clinical management of suppurative osteomyelitis, bisphosphonate-related osteonecrosis, and osteoradionecrosis: report of three cases and review of the literatureNon-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence.Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.Safety of long-term administration of bisphosphonates in elderly cancer patients.A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.Use of pamidronate in the management of acute cancer-related hypercalcemia in children.SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of acute hypercalcaemia in adult patients.Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness.[Real uses or just no damage? Bisphosphonates in oncology]Androgen-independent prostate cancer--the clinical problem of a growing pelvic tumour.Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review.Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw
P2860
Q26749965-6B3524B9-2FA9-4175-97FC-D4F5DBD14408Q26775300-38FBEE33-81A6-4D86-9F3D-9F16A82CF89DQ33841355-B1635CFE-020D-451D-AC42-BE843423292BQ33970570-C1881C06-EE11-4D96-871D-187E397EB124Q35550375-48921DEF-7546-404D-A8EE-836E9591782AQ35590055-264C3B9D-4AC6-49D3-8C40-926D17BE9E28Q35750641-15661ACB-4B9C-4CC6-B847-EEAFD723CF2FQ35872802-13269DFA-A5A6-4389-8F79-F7F2A4412EE8Q35884204-A51B7F53-C25C-496B-AFE0-45D79986A6F6Q36115924-7359CAA1-FBC5-4939-BFB4-349C7CD9FFD9Q36287932-F7231B60-FF01-4F01-B844-DB28E824ECDFQ36491477-FA10CC7E-7461-496E-8B0E-1AE7B7E22796Q36753894-CF8297D6-6E64-4BCC-9AED-8C46BAFC6D70Q36974038-C96A8508-35AE-4E6C-8D7B-E094C6EDF159Q37098197-46341AE8-3D34-4F3A-BAAF-8F33AD878319Q37270458-1DC052FA-623C-4515-98C7-45954AEF04A7Q38066405-E043B0F7-3AC0-4F37-BDA9-08355484AD65Q38728528-6456F64E-1CBB-43E4-889C-39A4B0EE40D1Q40521242-738AD8A2-58E7-427E-9FB9-F4EE55AE58B4Q40609773-4396F42B-39E0-4E5F-9F16-5BCF930AED91Q40678643-8C463493-3137-44F0-8DDA-D671B8F80C1DQ41664372-EE30BBFA-FA67-49EB-B703-39C3558F67A8Q42320852-29334C13-9593-4085-AA07-A10A63DB51E8Q42616085-F2761D37-1119-449D-AEBB-AD828C78EFD4Q50561804-343A6FF1-5799-40EA-846E-2432D349D5FEQ51487384-60DE0D04-9092-4BFD-9DCB-62F8C534971BQ52960729-5879FE3E-05E5-4F10-9C65-BC2076855C72Q53635529-625DFEA3-3508-4FE2-B16C-D1A881C462F2Q55426041-32ED81F6-2BDD-45F0-8BD9-A5736E852306Q58595822-D8FAFB41-893E-4722-BD39-57DE74F6BFF9
P2860
Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Single-dose intravenous therap ...... f 30-, 60-, and 90-mg dosages.
@en
type
label
Single-dose intravenous therap ...... f 30-, 60-, and 90-mg dosages.
@en
prefLabel
Single-dose intravenous therap ...... f 30-, 60-, and 90-mg dosages.
@en
P2093
P1476
Single-dose intravenous therap ...... f 30-, 60-, and 90-mg dosages.
@en
P2093
C J Vandepol
I C Henderson
L E Mallette
M A Zubler
S R Nussbaum
P304
P356
10.1016/0002-9343(93)90282-T
P407
P577
1993-09-01T00:00:00Z